Phase 4Completed
Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque (PREVENT)
a Multinational, Multicenter, Prospective, Open-label, Active-treatment-controlled Randomized Trial: Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque_PREVENT Trial
- Sponsor
- Seung-Jung Park (Academic or other)
- Enrolment
- 1,608 enrolled
- Conditions
- Coronary Artery Disease; Plaque, Atherosclerotic
- Interventions
- Coronary intervention; Optimal Medical treatment
- Ages
- adults, older adults
- Registry
- NCT02316886
Full record on ClinicalTrials.gov
From the registry
The primary aim of the trial is to determine whether preventive PCI with bioabsorbable vascular scaffolds (BVS) (early period) or everolimus-eluting stents (middle and late period) plus optimal medical therapy (OMT) on functionally insignificant (FFR \> 0.80) vulnerable coronary plaque, as determined by intracoronary imaging, would result in a significant reduction of the primary composite outcome of death from cardiac causes, target-vessel myocardial infarction (MI), target-vessel revascularization (TVR), and hospitalization for unstable or progressive angina at 2 years, when compared with OMT alone.
Primary outcomes
- Target vessel failure
History
Last registry update
Primary completion
Started
Registered